| Summary of the segment profit or loss |
The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended |
|
Six months ended |
|
June 30, |
|
June 30, |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Revenue |
$ |
128,231 |
|
$ |
5,130 |
|
$ |
133,909 |
|
$ |
52,731 |
Less: |
|
|
|
|
|
|
|
|
|
|
|
Research |
|
(3,830) |
|
|
(3,499) |
|
|
(7,438) |
|
|
(5,373) |
CMC and Quality |
|
(14,159) |
|
|
(13,675) |
|
|
(28,933) |
|
|
(26,608) |
Biomarkers |
|
(2,495) |
|
|
(1,222) |
|
|
(5,286) |
|
|
(2,452) |
Development and Compliance |
|
(12,611) |
|
|
(8,647) |
|
|
(27,486) |
|
|
(19,037) |
Infrastructure management and Facilities |
|
(7,749) |
|
|
(6,126) |
|
|
(15,828) |
|
|
(13,490) |
Commercial planning |
|
(2,561) |
|
|
(778) |
|
|
(6,445) |
|
|
(1,426) |
Support functions |
|
(9,139) |
|
|
(14,074) |
|
|
(21,073) |
|
|
(28,635) |
Other segment expenses(a) |
|
(6,987) |
|
|
(2,017) |
|
|
(1,981) |
|
|
1,038 |
Total operating expenses |
|
(59,531) |
|
|
(50,038) |
|
|
(114,470) |
|
|
(95,983) |
Operating profit/(loss) |
|
68,700 |
|
|
(44,908) |
|
|
19,439 |
|
|
(43,252) |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
1,376 |
|
|
1,543 |
|
|
2,721 |
|
|
2,219 |
Interest expense |
|
(526) |
|
|
— |
|
|
(526) |
|
|
— |
Gain on bargain purchase |
|
— |
|
|
22,155 |
|
|
— |
|
|
22,155 |
Other income (expense), net |
|
497 |
|
|
501 |
|
|
436 |
|
|
(170) |
Income tax expense |
|
(526) |
|
|
(680) |
|
|
(1,052) |
|
|
(1,305) |
Segment and consolidated net profit/(loss) |
$ |
69,521 |
|
$ |
(21,389) |
|
$ |
21,018 |
|
$ |
(20,353) |
(a)Other segment expenses includes reimbursements receivable for research and development tax and expenditure credits, depreciation, amortization and share-based compensation expenses.
|